Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2005-02-15
2005-02-15
Chen, Stacy Brown (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C424S130100, C424S211100
Reexamination Certificate
active
06855493
ABSTRACT:
The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection
REFERENCES:
patent: 4526938 (1985-07-01), Churchill et al.
patent: 4880078 (1989-11-01), Inoue et al.
patent: 5128326 (1992-07-01), Balazs et al.
patent: 5290540 (1994-03-01), Prince et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5679377 (1997-10-01), Bernstein et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5840298 (1998-11-01), Brams et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5866125 (1999-02-01), Brams et al.
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5912015 (1999-06-01), Bernstein et al.
patent: 5916597 (1999-06-01), Lee et al.
patent: 5934272 (1999-08-01), Lloyd et al.
patent: 5939068 (1999-08-01), Brams et al.
patent: 5955364 (1999-09-01), Brams et al.
patent: 5958765 (1999-09-01), Brams et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5985320 (1999-11-01), Edwards et al.
patent: 5989463 (1999-11-01), Tracy et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6117980 (2000-09-01), Gonzalez et al.
patent: 6537809 (2003-03-01), Brams
patent: 20020001798 (2002-01-01), Brams et al.
patent: WO 9105548 (1991-05-01), None
patent: WO 9219244 (1992-11-01), None
patent: WO 9605229 (1996-02-01), None
patent: WO 9620698 (1996-07-01), None
patent: WO 9732572 (1997-09-01), None
patent: WO 9734631 (1997-09-01), None
patent: WO 9744013 (1997-11-01), None
patent: WO 9831346 (1998-07-01), None
patent: WO 9915154 (1999-04-01), None
patent: WO 9920253 (1999-04-01), None
patent: WO 9966903 (1999-12-01), None
patent: WO 0029584 (2000-05-01), None
MedImmune, SYNAGIS (registered trademark) package insert, revised Oct. 23, 2002.*
Hacking et al., 2002, “Respiratory syncytial virus—viral biology and the host response,” J. Infection 45:18-24.
Heard et al., 1999, “Two neutralizing human RSV antibodies: cloning, expression, and characterization,” Mol. Med. 5:35-45.
Saez-Llorens et al., 1997, “Phase I/II open label multi dose escalation trial of a humanized respiratory synctial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children,” Abstract in Non HIV virology, ICAAC Toronto.
Subramanian et al., 1997, “Randomized double blind placebo controlled dose escalation trial of a humanized respiratory synctial virus monoclonal antibody in hugh risk infants,” Poster session infect. dis. 130A:768.
Sorbera et al., 1998, “Palivizumab,” Drugs of the Future 23:970-976.
Sorbera et al., 1998, “Palivizumab,” Drugs Data Report 20:702-703.
Abman et al., 1988, “Role of Respiratory Syncytial Virus in Early Hospitalizations for Respiratory Distress of Young Infants With Cystic Fibrosis”, J Pediatr. 113(5):826-30.
American Academy of Pediatrics Committee on Infectious Diseases: Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection. Pediatrics. Sep. 1993;92(3):501-4.
Beeler et al., 1989, “Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function”, J Virol. 63(7):2941-50.
Bentley et al., 1980, “Human immunoglobulin variable region genes—DNA Sequences of Two V Kappa Genes and a Pseudogene”, Nature 288:5194-5198.
Cleek et al., 1997, “Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application” Pro. Int'l Symp. Control. Rel Bioact. Mater. 24: 853-854.
Evans, A.S., 1989, Viral Infections of Humans, Epidemiology and Control, 3rded., 525-44.
Falsey et al., 1991, “Noninfluence Respiratory Virus Infection in Long-Term Care Facilities”, Infect Control Hosp Epidemiol. 12(10):602-8.
Felgen et al., 1987, Textbook of Pediatric Infectious Dieseases, WB Saunders, Philadelphia, pp. 1653-1675.
Garvie et al., 1980, “Outbreak of Respiratory Syncytial Virus Infection in the Elderly”, Br Med J. 281(6250):1253-4.
Glezen et al., 1981, “Risk of Respiratory Syncytial Virus Infection for Infants From Low-Income Families in Relationship to Age, Sex, Ethnic Group, and Maternal Antibody Level”, J Pediatr. 98(5):708-15.
Groothuis et al., 1988, “Respiratory Syncytial Virus Infection in Children with Bronchopulmonary Dysplasia”, Pediatrics. 82(2):199-203.
Groothuis et al., 1993, “Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-rish Infants and Yougn Children”, The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med. 329(21):1524-30.
Hall et al., 1979, “Neonatal Respiratory Syncytial Virus Infection”, N Engl J Med. 300(8):393-6.
Hall, C.B., 1993, Respriratory Syncytial: What We Know Now, Contemp. Pediatrics, 10:92-110.
Hemming et al., 1985, “Studies of Passive Immunotherapy for Infections of Respiratory Syncytial Virus in the Respiratory Tract of a Primate Model”, J Infect Dis. 152(5):1083-7.
Henderson et al., 1979, “Respiratory Synctial Virus Infections, Reinfections and Immunity. A Prospective, Longitudinal Study in Young Children”, N Engl J Med. 300(10):530-4.
Hertz et al., 1989, “Respiratory Syncytial Virus-Induced Acute Lung Injury in Adult Patients With Bone Marrow Transplants: a Clinical Approach and Review of the Literature”, Medicine (Baltimore). 68(5):269-81.
Howard et al., 1989, “Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits”, J Neurosurg. 71(1):105-12.
Johnson et al., 1987, “The G Glycoprotein of Human Respiratory Syncytial Viruses of Subgroups A and B: Extensive Sequence Divergence Between Antigenically Related Proteins”, Proc Natl Acad Sci U S A. 84(16):5625-9.
Johnson et al., 1987, “Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus”, J Infect Dis. 176(5):1215-24.
Kapikian et al., 1969, “An Epidemiologic Study of Altered Clinical Reactivity to Respiratory Syncytial (RS) Virus Infection in Children Previously Vaccinated With an Inactivated RS Virus Vaccine”, Am J Epidemiol. 89(4):405-21.
Kim et al., 1969, “Respiratory Syncytial Virus Disease in Infants Despite Prior Administration of Antigenic Inactivated Vaccine”, Am J Epidemiol. 89(4):422-34.
Lam et al., 1997, “Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery”, Proc. Int'l. Symp. Control Rel. Bioact. Mater. 24:759-760.
Lamprecht et al., 1976, “Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Virus”, J Infect Dis. 134(3):211-7.
Levy et al., 1985, “Inhibition of Calcification fo Bbioprosthetic Heart Valves by Local Controlled-release Diphosphonat
Huse William D.
Johnson Leslie S.
Koenig Scott
Watkins Jeffrey D.
Young James F.
Chen Stacy Brown
Jones Day
MedImmune, Inc.
LandOfFree
Methods of administering/dosing anti-RSV antibodies for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of administering/dosing anti-RSV antibodies for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of administering/dosing anti-RSV antibodies for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497678